drugset / Trial / NCT04596150
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
Timeline
- Start
- 2020-12-29
- Primary completion
- 2023-06-02
- Completion
- 2023-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacmilimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Praluzatamab Ravtansine | Unknown | 6 mg/kg | Intravenous |